国际皮肤性病学杂志    2004 30 (3): 197-199   ISSN: 2096-5540  CN: 32-1880/R   在防治HPV感染中树突状细胞的应用研究 李艳佳1, 齐凤英2 1. 河北医科大学第一医院皮肤科 石家庄 050031; 2. 河北医科大学病理教研室 收稿日期 2003-08-29  修回日期 null  网络版发布日期 null 参考文献  [1] Burk RD, Ho GY, Beardsley L, et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis, 1996,174:679-689. [2] Inaba K, Inaba M, Naito M,et al. Dendritic cell progenitors phagocyrose particulates, inluding bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med, 1993,178:479-488. [3] Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med, 1995,182:389-400. [4] Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 1994,179:1109-1118. [5] Coleman N, Birley HD, Renton AM,et al. Immunological events in regressing genital warts. Am J Clin Pathol, 1994,102:768-774. [6] Leigh IM, Glover MT. Cutaneous warts and tunours in immunosuppressed patients. J R Soc Med, 1995,88:61-62. [7] Mommaas AM, Mulder AA, Jordens R, et al. Human epidermal Langerhans cells lack functional mannose receptors and a fully developed endosomal/lysosomal compartment for loading of HLA class IImolecules. Eur J lmmunol, 1999,29:571-580. [8] Svensson M, Wick MJ. Classical MHC class I peptide presentation of a bacterial fusion protein by bone marrow-derived dendritic cells. Eur J Immunol, 1999,29:180-188. [9] Frazer IH, Thomas R, Zhou J,et al. Potential strategies utilised by papillomavirus to evade host immunity, Immunol Rev, 1999,168: 131-142. [10] Fausch SC, Da Silva DM, Rudolf MP, et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol,2002,169:3242-3249. [11] Arrese J, Paquet P, Claessens N,et al. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol, 2001,28:131-134. [12] Connor JP, Ferrer K, Kane JP,et al. Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia. Gynecol Oncol, 1999, 75:130-135. [13] McHugh RS, Ahmed SN, Wang YC, et al. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A, 1995,92:8059-8063. [14] Larsen CP, Ritchie SC, Pearson TC,et al. Functional expression of the costimulatory molecule, BT/BB1, on murine dendritic cell populations. J Exp Med, 1992,176:1215-1220. [15] Doan T, Chambers M, Street M,et al. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology, 1998, 244:352-364. [16] Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med, 1998, 4:37-42. [17] Tuting T, DeLco AB, Lotze MT, et al. Genetically modified bone marrow-derived dendritic cells expressing lumor-associated viral or"self" antigens induce antitumor immunity in vivo. Eur J Immunol,1997,27:2702-2707. [18] Tillman BW, Hayes TL, DeGruijl TD,et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against hunan papillomavirus 16-induced tumor cells in a murine model. Cancer Res, 2000,60:5456-5463. [19] Cheng WF, Hung CF, Hsu KF,et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomaL/lysosomal compartments. Hum Gene Ther, 2001,12:235-252. [20] Indrova M, Bubenik J, Simova J,et al. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro prining of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide. Int J Mol Med, 2001,7:97-100. [21] De Bruijn ML, Schuurhuis DH, Vierboom MP, et al. Inmunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res, 1998,58:724-731. [22] Kaufmann AM, Nieland J, Schinz M, et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer, 2001,92:285-293. 通讯作者: